Low Levels of Electromagnetic Fields to Treat Advanced Cancer

NCT00805337 | Unknown

• 1 other identifier: ADLG3
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Following the discovery of tumor-specific frequencies in patients with advanced cancer, compassionate treatment with tumor-specific frequencies administered at levels that are significantly below the levels generated by cell phone will be offered to patients with limited therapeutic options.

Conditions

Cancer

Keywords

Cancer amplitude-modulated electromagnetic fields

Interventions

Intrabuccally-administered amplitude-modulated RFEM DEVICE

Generation of amplitude-modulated electromagnetic fields: the device consists of a battery-driven radiofrequency (RF) electromagnetic field generator connected to a 1.5 meter long 50 Ohm coaxial cable, to the other end of which a spoon-shaped mouthpiece made of steel is connected with the inner conductor. The RF source of the device corresponds to a high-level amplitude-modulated class C amplifier operating at 27.12 MHz. The modulation frequency can be varied between 0.01 Hz and 150 kHz with a modulation depth of 85 ± 5%. The RF output is adjusted to 100 mW into a 50 Ohm load using a sinusoidal modulated test signal, which results in an emitting power identical to that of the device used in the treatment of insomnia (Pasche et al 1996, 19:327-336).

Also known as: Symtonic TheraBionic

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of cancer with advanced disease and limited therapeutic options

You may not qualify if:

• Any patient with curative treatment options

Sponsors & Collaborators

• Pasche, Boris, M.D.: lead

Related Publications (6)

• Kelly TL, Kripke DF, Hayduk R, Ryman D, Pasche B, Barbault A. Bright light and LEET effects on circadian rhythms, sleep and cognitive performance. Stress Med. 1997 Oct;13(4):251-8. doi: 10.1002/(SICI)1099-1700(199710)13:43.0.CO;2-0.

  PMID: 11542396 BACKGROUND

• Pasche B, Erman M, Hayduk R, Mitler MM, Reite M, Higgs L, Kuster N, Rossel C, Dafni U, Amato D, Barbault A, Lebet JP. Effects of low energy emission therapy in chronic psychophysiological insomnia. Sleep. 1996 May;19(4):327-36. doi: 10.1093/sleep/19.4.327.

  PMID: 8776791 BACKGROUND

• Lebet JP, Barbault A, Rossel C, Tomic Z, Reite M, Higgs L, Dafni U, Amato D, Pasche B. Electroencephalographic changes following low energy emission therapy. Ann Biomed Eng. 1996 May-Jun;24(3):424-9. doi: 10.1007/BF02660891.

  PMID: 8734063 BACKGROUND

• Reite M, Higgs L, Lebet JP, Barbault A, Rossel C, Kuster N, Dafni U, Amato D, Pasche B. Sleep inducing effect of low energy emission therapy. Bioelectromagnetics. 1994;15(1):67-75. doi: 10.1002/bem.2250150110.

  PMID: 8155071 BACKGROUND

• Amato D, Pasche B. An evaluation of the safety of low energy emission therapy. Compr Ther. 1993;19(5):242-7. No abstract available.

  PMID: 8275672 BACKGROUND

• Barbault A, Costa FP, Bottger B, Munden RF, Bomholt F, Kuster N, Pasche B. Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. J Exp Clin Cancer Res. 2009 Apr 14;28(1):51. doi: 10.1186/1756-9966-28-51.

  PMID: 19366446 DERIVED

MeSH Terms

Conditions

Neoplasms

Study Design

• Study Type: expanded access
• Sponsor Type: INDIV

Study Record Dates

• First Submitted: December 5, 2008
• First Posted: December 9, 2008
• Last Updated: December 9, 2008

Record last verified: 2008-12